(1) Initial active duty personnel. A single dose of trivalent OPV is
administered to all enlisted accessions. Officer candidates, ROTC cadets, and other
Reserve Components on initial active duty for training receive a single dose of OPV
unless prior booster immunization as an adult is documented.
(2) Booster doses. Booster doses of OPV are not routinely administered,
unless individuals are expected to be at exceptionally high risk of exposure to wild
poliovirus as a result of international travel. The need for booster doses of OPV is
individually determined by the respective attending physicians, based on ACIP
(3) Inactivated polio vaccine. Inactivated Polio Vaccine (IPV) is used as an
alternative to OPV for selected individuals as clinically indicated in accordance with
(1) Pre-exposure series. Rabies vaccine is administered to personnel with a
high risk of exposure (animal handlers; certain laboratory, field, and security personnel;
and personnel frequently exposed to potentially rabid animals in a nonoccupational or
recreational setting) in accordance with current ACIP recommendations.
(2) Post-exposure series. Rabies vaccine and rabies immune globulin (RIG)
administration will be coordinated with appropriate medical authorities following current
l. Tetanus--Diphtheria. A primary series of tetanus-diphtheria (Td) toxoid is
initiated for all recruits lacking a reliable history of prior immunization in accordance with
existing ACIP guidelines. Individuals with previous history of Td immunization receive a
booster dose upon entry to active duty and subsequently in accordance with ACIP
m. Typhoid. Typhoid vaccine is administered to alert forces and personnel
deploying to endemic areas. Either oral or intramuscular vaccine is used following
current ACIPI recommended dosage schedules.
n. Yellow Fever. Yellow fever immunization is required for all alert forces,
active duty personnel, or Reserve Components traveling to yellow fever endemic areas.
a. Chemoprophylaxis Requirements. Command medical officers review
indications for use and potential adverse effects of specific chemoprophylactic